TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39009116

Group type: EXPERIMENTAL
Intervention: C-reactive protein > 2 mg/l
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein levels (<1200 mmol/l)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein levels
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HbA1c >7%
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HgAbc1 >7%
Number of subjects: 62
Study: 39009130

Group type: EXPERIMENTAL
Intervention: Iliac branch devices (IBDs) - stainless steel
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Iliac branch devices (IBDs) - nitinol
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Iliac branch devices (IBDs) - overall
Number of subjects: 297
Study: 39009312

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (up to a 21 mg daily dose over 12 weeks)
Number of subjects: 29
Study: 39009356

Group type: EXPERIMENTAL
Intervention: Krill oil concentrate (KOC) 4 g/day for 24 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (vegetable oil mixture)
Number of subjects: 78
Study: 39009368

Group type: EXPERIMENTAL
Intervention: Opioid prescriptions at emergency department discharge
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Smaller, cause-specific opioid prescriptions
Number of subjects: 2240
Study: 39009453

Group type: EXPERIMENTAL
Intervention: AneuFix injectable polymer during endovascular aneurysm repair (EVAR)
Number of subjects: 25
Study: 39009709

Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna) treatment for 1 year
Number of subjects: 0
Study: 39009764

Group type: EXPERIMENTAL
Intervention: High consistent self-monitoring group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Low-decreasing self-monitoring group
Number of subjects: 150
Study: 39009776

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Wearable device data
Number of subjects: 53
Study: 39009785

Group type: EXPERIMENTAL
Intervention: LAWT-guided radiofrequency ablation
Number of subjects: 109
Study: 39009804

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 39009990

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait trainer Walkbot combined with physiotherapy (4 sessions per week of 40 min for 5 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isolated physiotherapy
Number of subjects: 23
Study: 39010013

Group type: EXPERIMENTAL
Intervention: Trendelenburg position duration
Number of subjects: 25
Study: 39010089

Group type: EXPERIMENTAL
Intervention: Web-based learning group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional learning group
Number of subjects: 0
Study: 39010098

Group type: EXPERIMENTAL
Intervention: Green Approach to Improved Nutritional support for patients with cancer (GAIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current nutritional support practices
Number of subjects: 0
Study: 39010160

Group type: EXPERIMENTAL
Intervention: EBQI-IC (individual coaching)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EBQI-LC (learning collaborative)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 39010171

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray 0.2 µg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray 0.5 µg/kg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline nasal spray (Control)
Number of subjects: 150
Study: 39010208

Group type: EXPERIMENTAL
Intervention: Prompt closure of external ventricular drain (EVD)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Gradual weaning of external ventricular drain (EVD)
Number of subjects: 244
Study: 39010232

Group type: EXPERIMENTAL
Intervention: Prenatal affective cognitive training (PACT)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: PACT
Number of subjects: 292

Group type: COMPARATOR
Intervention: CAU
Number of subjects: 292
Study: 39010659

Group type: EXPERIMENTAL
Intervention: Achilles tendon resting angle (ATRA) symmetry at 2 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tegner score at 2 and 12 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Achilles tendon total rupture score (ATRS) at 12 months
Number of subjects: 35
Study: 39010683

Group type: EXPERIMENTAL
Intervention: Kavalactones
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 39010708

Group type: EXPERIMENTAL
Intervention: Voriconazole treatment during inflammation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate or high CRP levels (>50 mg/L)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Longitudinal data analysis with and without inflammation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Voriconazole plasma concentrations during inflammation
Number of subjects: 39
Study: 39010748

Group type: EXPERIMENTAL
Intervention: Training to deal with distractions and conflicting situations in activities of daily living after TBI
Number of subjects: 0
Study: 39010780

Group type: EXPERIMENTAL
Intervention: Technology-based parent school program (10-week duration, including five website modules, five online interactive group trainings, and counseling)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Technology-based parent school program
Number of subjects: 48
Study: 39011096

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial plus RB-PDT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical antimicrobial plus sham RB-PDT
Number of subjects: 0
Study: 39011360

Group type: EXPERIMENTAL
Intervention: NIH Stroke Scale (NIHSS)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Intracerebral hemorrhage score (ICH score)
Number of subjects: 384
Study: 39011819

Group type: EXPERIMENTAL
Intervention: Frictionless group using closing T-loops for en-masse retraction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Friction group using NiTi coil springs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Friction group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Frictionless group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 39011963

Group type: EXPERIMENTAL
Intervention: Preeclampsia (PE) children
Number of subjects: 267

Group type: COMPARATOR
Intervention: Non-preeclampsia (non-PE) children
Number of subjects: 267
Study: 39012090

Group type: EXPERIMENTAL
Intervention: Fosmanogepix (FMGX)
Number of subjects: 0
Study: 39012102

Group type: EXPERIMENTAL
Intervention: TRL1068 (administered via a single pre-surgical intravenous infusion in doses of 6, 15, and 30 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (administered to 4 patients)
Number of subjects: 15
Study: 39012221

Group type: EXPERIMENTAL
Intervention: T-DXd (Trastuzumab deruxtecan)
Number of subjects: 0
Study: 39012226

Group type: EXPERIMENTAL
Intervention: Pyrazinamide treatment, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study: 39012233

Group type: EXPERIMENTAL
Intervention: H2O2 and HA
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 114
Study: 39012250

Group type: EXPERIMENTAL
Intervention: CT imaging with normalized join-count analysis for emphysema progression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline CT images
Number of subjects: 0
Study: 39012500

Group type: EXPERIMENTAL
Intervention: Home-based resistance training
Number of subjects: 181
Study: 39012630

Group type: EXPERIMENTAL
Intervention: Behavioral economics-informed intervention bundle including default scheduling of postpartum PCP appointments and tailored messages
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 360
Study: 39012717

Group type: EXPERIMENTAL
Intervention: Setrusumab 20 mg/kg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Setrusumab 8 mg/kg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 39012722

Group type: EXPERIMENTAL
Intervention: BPS webSTAIR
Number of subjects: 178

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 178
Study: 39012843

Group type: EXPERIMENTAL
Intervention: Nutraceutical composition (yeast β-glucan, prebiotics, minerals, and silymarin)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study: 39012877

Group type: EXPERIMENTAL
Intervention: treadmill + Gamified Virtual Reality Environment (GVRE) + tDCS training group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: treadmill + GVRE training group
Number of subjects: 78

Group type: COMPARATOR
Intervention: treadmill training group
Number of subjects: 78
Study: 39012930

Group type: EXPERIMENTAL
Intervention: Personalized prescription of pacing (PPoP) for 6 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Backup pacing
Number of subjects: 17
Study: 39012942

Group type: EXPERIMENTAL
Intervention: LA HFpEF shape score
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: LA roof dilation
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall LA enlargement
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cardiovascular hospitalization
Number of subjects: 68
Study: 39012946

Group type: EXPERIMENTAL
Intervention: Combination of hyperglycemia with low HDL cholesterol
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Combination of hyperglycemia with high systemic blood pressure
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Rapid plaque progression
Number of subjects: 1200
Study: 39013131

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 42
Study: 39013133

Group type: EXPERIMENTAL
Intervention: Exome+ sequencing (Helix Inc, San Mateo, CA)
Number of subjects: 44306
Study: 39013194

Group type: EXPERIMENTAL
Intervention: Dashboard plus discharge checklist
Number of subjects: 260

Group type: COMPARATOR
Intervention: Dashboard
Number of subjects: 260

Group type: COMPARATOR
Intervention: Pre-implementation
Number of subjects: 260
Study: 39013265

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 39013470

Group type: EXPERIMENTAL
Intervention: Allogeneic CD19-targeted CAR-T therapy
Number of subjects: 3
Study: 39013643

Group type: EXPERIMENTAL
Intervention: Minimally invasive spine surgery (MISS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard posterior spine fusion
Number of subjects: 126
Study: 39013644

Group type: EXPERIMENTAL
Intervention: Psychological autopsy method integrating anthropological and psycholinguistic approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory multimethod strategy combining epidemiological, anthropological, psycholinguistic, and psychological methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semiautomated analysis of the discourse of relatives bereaved by suicide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall results and perspectives communicated to bereaved relatives
Number of subjects: 0
Study: 39013653

Group type: EXPERIMENTAL
Intervention: 3M Tegaderm Antimicrobial IV Advanced Securement dressing
Number of subjects: 2924

Group type: COMPARATOR
Intervention: Standard polyurethane dressing
Number of subjects: 2924
Study: 39013654

Group type: EXPERIMENTAL
Intervention: mifepristone (Korlym)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1000
Study: 39013870

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard-of-care (carboplatin plus paclitaxel)
Number of subjects: 61
Study: 39013886

Group type: EXPERIMENTAL
Intervention: NeoAdjuvant ChemoTherapy (NACT) + Pembrolizumab (P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NeoAdjuvant ChemoTherapy (NACT)
Number of subjects: 0
Study: 39014136

Group type: EXPERIMENTAL
Intervention: CRP quartile Q1 (<8 mg/L)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: CRP quartile Q2 (8-28 mg/L)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: CRP quartile Q3 (>28-69 mg/L)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: CRP quartile Q4 (>69 mg/L)
Number of subjects: 772
Study: 39014267

Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy Lifestyle attention control
Number of subjects: 49
Study: 39014316

Group type: EXPERIMENTAL
Intervention: Apical enlargement to 35#/0.04 and 40#/0.04 for Group A (mesial and distal canals respectively)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Apical enlargement to 40#/0.04 and 45#/0.04 for Group B (mesial and distal canals respectively)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both groups measured pain scores at 12, 24, and 72 hours, and after one week
Number of subjects: 25
Study: 39014369

Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 475
Study: 39014430

Group type: COMPARATOR
Intervention: Standard weaning (SBT: 30-min PSV8 without PEEP followed by extubation with continuous suctioning)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Lung-volume-preservation weaning (SBT: 30-min PSV8 + 5 cmH2O PEEP)
Number of subjects: 1600
Study: 39014448

Group type: EXPERIMENTAL
Intervention: Low dose of Morphine Hydrochloride (intravenous titration followed by subcutaneous relay)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 39014463

Group type: EXPERIMENTAL
Intervention: Anthracycline therapy
Number of subjects: 59
Study: 39014495

Group type: EXPERIMENTAL
Intervention: Standardized management of HFNC weaning guided by clinical decision support (CDS)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study: 39014498

Group type: EXPERIMENTAL
Intervention: Narrowband UVB (NB-UVB) combined with optimal topical therapy (OTT) for a minimum of 3 months and 8 to 16 weeks of NB-UVB
Number of subjects: 316

Group type: COMPARATOR
Intervention: Optimal topical therapy (OTT) for 3 months
Number of subjects: 316
Study: 39014512

Group type: EXPERIMENTAL
Intervention: Operator-independent continuous ultrasound monitoring (CUSdi)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard ultrasound measurement of EXdi and PCVdi
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard ultrasound measurement of Pdi derived parameters
Number of subjects: 49
Study: 39014551

Group type: EXPERIMENTAL
Intervention: Pre-TAVI Lung Ultrasound (LUS) assessment of pulmonary congestion (PC)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Post-TAVI Lung Ultrasound (LUS) assessment of pulmonary congestion (PC)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Composite endpoint of all-cause mortality, hospitalization for heart failure, and urgent medical visits for worsening dyspnoea at 12-month follow-up
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Pre-TAVI LUS-PC
Number of subjects: 127
Study: 39014980

Group type: EXPERIMENTAL
Intervention: Primary control engagement coping (e.g., problem-solving)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Secondary control engagement coping (e.g., positive thinking)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Disengagement coping (e.g., avoidance)
Number of subjects: 198
Study: 39015065

Group type: EXPERIMENTAL
Intervention: Caregiver Global Impression of Change in memory or daily activities
Number of subjects: 0
Study: 39015176

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 39015189

Group type: EXPERIMENTAL
Intervention: Significant tricuspid regurgitation (TR)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Significant TR
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: NTpro-BNP
Number of subjects: 93
Study: 39015350

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Current Antiretroviral Regimen (CAR)
Number of subjects: 1234
Study: 39015674

Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow-Derived Mononuclear Cell Infusion into Renal Arteries
Number of subjects: 5
Study: 39016010

Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment
Number of subjects: 8442

Group type: COMPARATOR
Intervention: Standard SBP treatment
Number of subjects: 8442
Study: 39016024

Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39016053

Group type: EXPERIMENTAL
Intervention: Aumolertinib
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 106
Study: 39016202

Group type: EXPERIMENTAL
Intervention: Optimized transcutaneous auricular vagus nerve stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39016261

Group type: EXPERIMENTAL
Intervention: Digital care program (DCP)
Number of subjects: 5032
Study: 39016317

Group type: EXPERIMENTAL
Intervention: Total breast reconstruction with autologous fat transfer (AFT)
Number of subjects: 0
Study: 39016381

Group type: EXPERIMENTAL
Intervention: Multimodal enhanced recovery pathway including preoperative and postoperative nonopioid analgesia with oral acetaminophen, gabapentin, and ketorolac.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard of care without multimodal analgesia.
Number of subjects: 89
Study: 39016593

Group type: EXPERIMENTAL
Intervention: Molecular dihydrogen (H2) inhalation therapy (3.6% H2 and 96.4% N2)
Number of subjects: 12
Study: 39016594

Group type: EXPERIMENTAL
Intervention: Linezolid (LZD) treatment over 14 days
Number of subjects: 106
Study: 39016623

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39016667

Group type: EXPERIMENTAL
Intervention: Text message intervention (51 messages over 1000 days)
Number of subjects: 0
Study: 39017661

Group type: EXPERIMENTAL
Intervention: Oral microbiome in patients with oral cGVHD
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral and gut microbiota overlap
Number of subjects: 80

Group type: COMPARATOR
Intervention: Longitudinal trajectories of oral and gut microbiomes
Number of subjects: 80
Study: 39017667

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (arm A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Adavosertib plus carboplatin (arm B)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ceralasertib plus olaparib (arm C)
Number of subjects: 72
Study: 39017697

Group type: EXPERIMENTAL
Intervention: Late-PN
Number of subjects: 4640

Group type: COMPARATOR
Intervention: Early-PN
Number of subjects: 4640
Study: 39017806

Group type: EXPERIMENTAL
Intervention: Erdafitinib
Number of subjects: 27

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 27
Study: 39018016

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg with concomitant SSRI/SNRI use in UC (n=67)
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Ozanimod 0.92 mg without concomitant SSRI/SNRI use in UC (n=1091)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg with concomitant SSRI/SNRI use in RMS (n=274)
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Ozanimod 0.92 mg without concomitant SSRI/SNRI use in RMS (n=1982)
Number of subjects: 1158
Study: 39018020

Group type: EXPERIMENTAL
Intervention: Vitiligo
Number of subjects: 9460

Group type: COMPARATOR
Intervention: Matched controls without vitiligo
Number of subjects: 9460
Study: 39018024

Group type: EXPERIMENTAL
Intervention: Cohort study with pragmatic definition of compensated cirrhosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definitions of incident and recompensated ascites, overt hepatic encephalopathy, variceal hemorrhage, bleeding because of portal gastropathy, and hepatocellular carcinoma
Number of subjects: 0
Study: 39018038

Group type: EXPERIMENTAL
Intervention: Cendakimab 720 mg, once weekly
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Cendakimab 720 mg, every 2 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Cendakimab 360 mg, every 2 weeks
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 39018053

Group type: EXPERIMENTAL
Intervention: EHR-based nudge intervention targeting surgeons
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control period (pre-intervention)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Intervention period (post-intervention)
Number of subjects: 387
Study: 39018071

Group type: EXPERIMENTAL
Intervention: Parent-guided enhanced developmental intervention (usual care plus infant massage, enhanced visual stimulation, auditory stimulation, social interactions, and support for motor development)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (support for lactation, kangaroo care, and routine developmental therapies)
Number of subjects: 100
Study: 39018103

Group type: EXPERIMENTAL
Intervention: Mobile health data collection using Fitbit smartwatch and smartphone app for continuous collection of physical activity, sedentary behavior, sleep, and dietary data over 2 years, along with biometric assessments and questionnaires at 3 time points (baseline, 12-, and 24-month follow-up).
Number of subjects: 776
Study: 39018119

Group type: EXPERIMENTAL
Intervention: Urine pH-Ammonium Acid/Base Score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39018154

Group type: EXPERIMENTAL
Intervention: Selonsertib
Number of subjects: 0
Study: 39018444

Group type: EXPERIMENTAL
Intervention: Quantifiable spike antibody (Ab)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Unquantifiable spike antibody (Ab)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Quantifiable nucleocapsid antigen (N Ag)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Unquantifiable nucleocapsid antigen (N Ag)
Number of subjects: 209
Study: 39018512

Group type: EXPERIMENTAL
Intervention: Ofatumumab 20 mg every 4 weeks
Number of subjects: 1882

Group type: COMPARATOR
Intervention: Teriflunomide 14 mg once daily
Number of subjects: 1882